Home a Keryx revenue falls short despite support of analysts, Baupost
 

Keywords :   


a Keryx revenue falls short despite support of analysts, Baupost

2015-08-05 20:24:17| Biotech - Topix.net

Boston-based Keryx Biopharmaceuticals has reported what it calls "progress" in the launch of its drug for dialysis patients, called Auryxia, in recent months, including expanded insurance coverage in the U.S., success in contacting potential prescribers and likely European approval in coming months. Keryx , which moved its headquarters to Boston last year from New York City, reported Auryxia sales of just $1.8 million in the second quarter since the drug's launch.

Tags: support short falls revenue

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
05.11Shoppers warned over luxury advent calendar scams
05.11Durable Floor Coating from HMG Paints Transforms FC United\'s SMRE Bar
05.11Teknos Poland Honored by Farby i Lakiery
05.11Xumo teams up with Target to offer Hisense Xumo TVs
05.11KT launches 8K AI-powered IPTV set-top box
05.11Tropical Storm Rafael Graphics
More »